What Is the Normal Range for a FIB-4 Score?

A FIB-4 score below 1.3 is generally considered normal, meaning the likelihood of significant liver fibrosis (scarring) is low. Scores between 1.3 and 2.67 fall into an indeterminate zone that usually requires further testing, and scores above 2.67 suggest a higher probability of advanced fibrosis. Those thresholds are widely used in clinical guidelines, but they shift depending on your age, and the score performs quite differently across various liver conditions and populations.

What FIB-4 Actually Measures

FIB-4 is not a direct measurement of liver scarring. It is a calculated index that combines four routine blood-test and demographic values: your age, your AST level, your ALT level, and your platelet count. A doctor or a lab computer plugs those numbers into a formula and out comes a single number. The score was originally developed to estimate liver fibrosis in people co-infected with HIV and hepatitis C, and it has since been validated across a wide range of liver diseases, including fatty liver disease and hepatitis B.

The appeal of FIB-4 is that it requires no special equipment, no imaging, and no liver biopsy. Any standard set of blood work that includes a complete blood count and a liver panel gives your doctor everything needed to calculate it. Many electronic health record systems now compute FIB-4 automatically, which is why the test has become a front-line screening tool in primary care rather than something reserved for liver specialists.

The Three Risk Tiers

Clinical guidelines divide FIB-4 results into three categories, and understanding which tier your score falls into matters more than fixating on the exact number:

Below 1.3 (low risk): Advanced fibrosis is unlikely. In most populations studied, roughly two-thirds of patients fall here, and no further fibrosis workup is typically needed.
1.3 to 2.67 (indeterminate): The score alone cannot tell whether you have significant fibrosis. Additional testing is recommended. About one in four patients lands in this zone.
Above 2.67 (high risk): There is a meaningful probability of advanced fibrosis. Referral to a hepatologist and further evaluation, often with imaging or biopsy, is standard practice. Around one in ten patients ends up here.

Those proportions come from a large cohort study of nearly 13,000 patients with metabolic liver disease, where baseline FIB-4 classified about 66% as low risk, 24% as indeterminate, and 10% as high risk.

Why Age Changes the Cutoffs

Because age is baked into the FIB-4 formula, getting older automatically pushes your score higher, even if your liver hasn’t changed. A 70-year-old with the exact same AST, ALT, and platelet values as a 35-year-old will get a substantially higher FIB-4. This creates a real clinical problem: the standard 1.3 cutoff flags a huge number of older adults as “indeterminate” or “high risk” when many of them have perfectly healthy livers.

To address this, many guidelines now recommend raising the lower cutoff to 2.0 for people aged 65 and older. One study found that in patients over 65, the standard cutoff of 1.3 had perfect accuracy for ruling out advanced fibrosis, but it cast an extremely wide net, catching nearly everyone. Raising the cutoff to 2.0 still maintained strong accuracy, correctly ruling out advanced fibrosis about 83% of the time, while dramatically reducing unnecessary follow-up testing.

⁴

A multicenter Japanese study went further, proposing different cutoffs for each decade of life. For people under 50, the suggested low cutoff was about 1.05. For those in their 50s, it was 1.24. For the 60s, it jumped to 1.88, and for people 70 and older, the low cutoff was 1.95 while the high cutoff reached 4.56. These age-stratified thresholds improved diagnostic accuracy across all age groups.

⁵

A population-based screening study similarly suggested that for people older than 70, raising the FIB-4 threshold to 2.0 and excluding those over 80 entirely would make mass screening far more practical and cost-effective, because otherwise the number of false-positive results overwhelms the system.

⁶

The Problem for Younger Adults

The same formula that inflates scores in older adults can suppress them in younger people, potentially missing real fibrosis. In adults under about 35, FIB-4 scores tend to cluster at very low values even when significant scarring is present. One study found that FIB-4 had good accuracy in younger adults when using standard thresholds, with an area under the curve of about 82%, but only because the test was highly specific in that group. Its sensitivity was extremely low, meaning it correctly identified people without fibrosis but frequently missed those who had it.

⁷

Research into younger patients with fatty liver disease found that the standard rule-out thresholds had essentially zero sensitivity for significant fibrosis. When researchers recalculated optimal cutoffs specifically for younger populations, sensitivity improved dramatically, jumping from near 0% to about 63% for FIB-4. This strongly suggests that the standard 1.3 cutoff is simply too high to be useful in people under 40 or so, and younger patients with risk factors for liver disease should not be reassured by a “normal” FIB-4 alone.

⁸

What Happens When Your Score Is Indeterminate

Landing in the 1.3-to-2.67 range is common and can feel unsettling, but it does not mean something is wrong. It means the blood test alone cannot give a clear answer. The standard next step is a second-line test, and two are commonly used: liver stiffness measurement by elastography (often called FibroScan) or a specialized blood panel like the Enhanced Liver Fibrosis (ELF) test.

When researchers applied the ELF test to patients whose FIB-4 fell in the indeterminate range, about 56% of those patients turned out to have results consistent with significant fibrosis. That confirmation rate was much higher, around 80%, for people in the high-risk FIB-4 group above 2.67. Using this two-step approach in a primary care setting, about a quarter of all patients screened initially landed in the indeterminate zone.

⁹

A separate study applying a similar two-step algorithm found that using an ELF cutoff of 9.8 for the indeterminate FIB-4 group produced good overall accuracy: about 68% sensitivity and 90% specificity. More practically, it meant that roughly two-thirds of patients with indeterminate FIB-4 scores could avoid further invasive testing because the ELF test resolved their status without the need for elastography or biopsy.

¹⁰

Another approach uses elastography as the second step. In the large cohort study mentioned earlier, applying liver stiffness measurement to the indeterminate group shrank that gray zone from about 24% of patients to under 14%, while expanding the confidently low-risk group from 66% to over 81%.

How FIB-4 Performs Across Different Liver Diseases

The score was not designed as a one-size-fits-all tool, and its accuracy varies depending on the underlying liver condition. In metabolic fatty liver disease (now called MASLD, previously NAFLD), FIB-4 is most widely used and studied. But even there, the picture is imperfect. A multicenter study of biopsy-proven MASLD patients found that the standard FIB-4 thresholds produced a false-positive rate of about 43% and a false-negative rate of about 26% for identifying significant fibrosis. Those are not small miss rates. The study’s authors argued that guideline-based risk stratification may misclassify a significant proportion of patients, particularly when the goal is deciding who qualifies for newer drug treatments aimed at moderate fibrosis.

¹¹

For hepatitis B, a meta-analysis found that FIB-4 worked reasonably well at higher cutoffs. At a threshold above 2.0, specificity was about 95% and the area under the curve was 0.90, suggesting good accuracy for confirming advanced fibrosis. Interestingly, FIB-4 appeared to perform better in hepatitis B than in hepatitis C, where it was originally developed.

¹²

That said, the optimal cutoffs shift by disease. One review reported that accurate cutoffs for hepatitis B were 1.0 and 2.65, while for hepatitis C the boundaries were 1.45 and 3.25, notably different from the standard 1.3 and 2.67 used in general practice.

¹³

For alcohol-related liver disease, a study of Japanese male workers found that heavy drinkers (consuming 40 or more grams of ethanol daily) had more than four times the odds of reaching a FIB-4 score of 2.67 or higher. Over a ten-year follow-up, heavy drinkers at baseline had roughly double the risk of progressing to that high-risk threshold. Very elevated GGT levels, a marker of heavy alcohol use, were an even stronger predictor than drinking quantity itself.

¹⁴

Tracking FIB-4 Over Time

A single FIB-4 score is a snapshot, and snapshots can be misleading. Current guidelines suggest rechecking every two to three years, but the guidance is vague about how to weigh earlier scores against newer ones. One primary care study found that about a third of patients had a higher-risk FIB-4 score on a subsequent test compared to their initial value, underscoring that fibrosis risk is not static.

¹⁵

A large Swedish cohort study of nearly 127,000 people examined what happened when FIB-4 was measured twice within five years. Moving from a low- or intermediate-risk group to the high-risk group between tests was associated with roughly an 8-fold increase in the risk of severe liver disease. People who scored high risk at both measurements faced about a 17-fold increased risk compared to those who stayed in the low-risk group at both time points. Yet almost half of all severe liver events still occurred in people who were consistently classified as low risk, a humbling reminder of the test’s limitations.

¹⁶

The practical takeaway is that a single reassuring score is worth less than a stable trend. If you have risk factors for liver disease, periodic rechecking gives a much clearer picture than any one-time result.

How FIB-4 Compares to Other Noninvasive Scores

FIB-4 is not the only blood-based fibrosis score. The APRI (AST-to-Platelet Ratio Index) and the NFS (NAFLD Fibrosis Score) are frequently used alternatives, and newer scores are emerging. A systematic review comparing their prognostic accuracy for predicting fibrosis progression in fatty liver disease found that FIB-4 and NFS performed similarly, with areas under the curve ranging from about 0.65 to 0.83 depending on the study, while APRI was somewhat less accurate, topping out around 0.72.

¹⁷

Head-to-head comparisons in biopsy-confirmed populations tell a consistent story. In one study from a Mexican population with MASLD, FIB-4 had the highest area under the curve (0.80) compared to APRI (0.79), HFS (0.70), and NFS (0.68).

¹⁸

A separate biopsy-validation study found that FIB-4, APRI, and the AST/ALT ratio could detect advanced fibrosis with areas under the curve between 0.68 and 0.79. No single blood-based score dramatically outperforms the others, which is partly why guidelines favor a two-step approach where FIB-4 serves as a first-pass screening tool and a second, more precise test resolves borderline cases.

¹⁹

FIB-4 in Children

The score was developed in adults and does not translate well to younger populations. Because age is part of the calculation, children inherently produce very low FIB-4 values. A study of pediatric MASLD patients found that the FIB-4 cutoff that best distinguished fibrosis in children was around 0.215, a value so low that it bears no resemblance to the adult thresholds.

²⁰

Children also tend to maintain normal platelet counts even in the presence of significant scarring, which further undermines the formula. Research evaluating adult fibrosis scores in children with fatty liver disease found poor performance across the board, and the authors concluded that developing a reliable pediatric-specific fibrosis score remains an urgent unmet need.

²¹

Predicting More Than Liver Scarring

FIB-4 was designed to estimate fibrosis, but elevated scores appear to carry prognostic information well beyond the liver. In a Japanese multicenter registry of patients with atrial fibrillation, those with FIB-4 scores in the highest tier (2.51 or above) had about a 70% higher rate of cardiovascular events and a 43% higher rate of death from any cause, even after adjusting for standard cardiac risk factors.

²²

A longitudinal study of people with obesity or type 2 diabetes found that FIB-4 predicted future liver events, cardiovascular events, and death from all causes, and these associations held up after accounting for conventional cardiovascular risk at the starting point. The liver and the heart share overlapping risk factors, particularly insulin resistance and chronic inflammation, so a score designed for one organ turns out to carry useful signals for the other.

²³

Common Reasons for a Falsely High Score

Because FIB-4 uses only four inputs, anything that temporarily alters those inputs can throw the number off. A few scenarios produce misleadingly elevated scores without any underlying fibrosis:

Age alone: As discussed, aging pushes the score up mechanically. A healthy 72-year-old may get a borderline score purely because of the formula’s age weighting.
Acute liver injury: A transient spike in AST from a medication reaction, a viral illness, or a bout of heavy drinking will inflate the score until enzyme levels normalize.
Low platelet counts from non-liver causes: Immune conditions, bone marrow disorders, or even some medications can lower platelets independently of liver disease, which drives FIB-4 up.
Intense exercise: Strenuous physical activity can temporarily raise AST because the enzyme is also released from muscle, not just from liver cells.

These confounders are a major reason FIB-4 carries meaningful false-positive rates, particularly in primary care screening where the population includes many people without liver disease at all. One analysis noted that FIB-4 has limited accuracy in predicting liver stiffness, resulting in high rates of false positives and negatives in the fatty-liver-disease population.

²⁴

If your FIB-4 comes back elevated and you or your doctor suspect a confounding factor, the simplest approach is to repeat the test once the transient condition resolves. A persistently elevated score carries much more weight than a single high reading.

Mass Screening and What It Means for You

With electronic health records now computing FIB-4 automatically, more people are seeing this number without having specifically asked for it. Across several international guidelines for managing fatty liver disease in people with type 2 diabetes, about 12% of patients were identified as needing specialist referral, regardless of which guideline was applied.

²⁵

That consistency across guidelines is reassuring, but it also raises a capacity question. One institution that implemented automated FIB-4 screening in its primary care system found that the sudden visibility of elevated scores created a potential bottleneck, with demand for follow-up elastography potentially overwhelming hepatology clinics if every flagged patient was referred at once.

For you as a patient, the practical lesson is this: if your FIB-4 shows up on a lab report and falls below 1.3 (or below 2.0 if you are over 65), you can generally feel confident that advanced liver scarring is unlikely. If it falls in the gray zone, expect a follow-up test rather than an immediate alarm. And if it is elevated, treat it as a signal worth investigating, not a diagnosis. FIB-4 is the smoke detector, not the fire report.